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Abstract
Background: Thromboxane synthase (TXS) metabolises prostaglandin H2 into thromboxanes, which are
biologically active on cancer cells. TXS over-expression has been reported in a range of cancers, and associated
with a poor prognosis. TXS inhibition induces cell death in-vitro, providing a rationale for therapeutic intervention.
We aimed to determine the expression profile of TXS in NSCLC and if it is prognostic and/or a survival factor in the
disease.
Methods: TXS expression was examined in human NSCLC and matched controls by western analysis and IHC. TXS
metabolite (TXB2) levels were measured by EIA. A 204-patient NSCLC TMA was stained for COX-2 and downstream
TXS expression. TXS tissue expression was correlated with clinical parameters, including overall survival. Cell
proliferation/survival and invasion was examined in NSCLC cells following both selective TXS inhibition and stable
TXS over-expression.
Results: TXS was over-expressed in human NSCLC samples, relative to matched normal controls. TXS and TXB2
levels were increased in protein (p < 0.05) and plasma (p < 0.01) NSCLC samples respectively. TXS tissue expression
was higher in adenocarcinoma (p < 0.001) and female patients (p < 0.05). No significant correlation with patient
survival was observed. Selective TXS inhibition significantly reduced tumour cell growth and increased apoptosis,
while TXS over-expression stimulated cell proliferation and invasiveness, and was protective against apoptosis.
Conclusion: TXS is over-expressed in NSCLC, particularly in the adenocarcinoma subtype. Inhibition of this enzyme
inhibits proliferation and induces apoptosis. Targeting thromboxane synthase alone, or in combination with
conventional chemotherapy is a potential therapeutic strategy for NSCLC.
Introduction
Lung cancer is the leading cause of cancer related death
in the developed world, accounting for 12% of deaths
worldwide [1]. Median survival for the majority of
patients with advanced non-small cell lung cancer
(NSCLC) is 18 months and 9 months for locally
advanced or metastatic disease respectively [2]. Current
therapeutic strategies are relatively ineffective, which is
reflected by an overall survival rate of just 15% [3].
Arachidonic acid (AA) can be converted to various eico-
sanoids by enzymes such as cyclooxygenase (COX), lipox-
ygenase (LOX), or epoxygenases (cytochrome P-450). The
cyclooxygenase enzymes consist of two isoforms, COX-1
and COX-2, which catalyze the first step in the generation
of downstream prostanoids from arachidonic acid [4].
COX-derived prostanoids are involved in a wide range of
physiological processes, but have also been implicated in a
range of disease states, such as arthritis, heart disease, and
pulmonary hypertension [5]. In the past number of years,
there has been significant interest in the role of COX-2 in
cancer development and progression. Expression of this
enzyme has been associated with a poor prognosis in lung
cancer [6-8], while a potential role for COX-2 in lung can-
cer chemoprevention has been investigated in a number of
clinical trials [9-11]. However, chronic administration of
high concentrations of selective COX-2 inhibitors has
been associated with an increased risk of adverse cardio-
vascular events [12-14]. Recent studies suggest that the
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be attributable to downstream products of AA metabo-
lism. Increased COX-2 expression is associated with
increased levels of downstream enzymes required for pros-
tanoid synthesis, such as prostaglandin E2 synthase (PGE-
S), prostaglandin D2 synthase (PGD-S), and thromboxane
A2 synthase [15]. However, the relationship of prostanoid
profile to cancer growth is not fully understood.
Thromboxane synthase (TXS) activity was first
described in platelets [16]. The enzyme was later purified
as a 60 kDa hemoprotein with spectroscopic characteris-
tics of the cytochrome P-450 family [17]. TXS metabolises
the cyclooxygenase product, prostaglandin H2, into
thromboxanes, which are biologically active on cancer
cells. TXA2 is a potent vascoconstrictor and bronchocon-
strictor, as well as a potent promoter of platelet aggrega-
tion [18,19]. TXS and its product, TXA2, have been shown
to promote proliferation, invasion, metastasis and angio-
genesis in a variety of cancers [20-24]. TXS over-expres-
sion has been reported in thyroid, prostate, colorectal, and
bladder cancer [20-22,24,25]. Over-expression of this
enzyme has been associated with a significant reduction in
survival in bladder cancer [21]. In addition, analysis of
prostate tumour specimens revealed increased TXS levels
in patient samples of advanced stage and grade [22,25].
Thromboxane synthase expression has been associated
with tumour growth in a variety of cancers, both in-vivo
and in-vitro [21,24,26,27]. A number of these studies have
demonstrated a significant reduction in tumour cell
growth following selective TXS inhibition [21,24,26], sug-
gesting that targeting this enzyme may have therapeutic
efficacy in cancer. Specific thromboxane synthase inhibi-
tion has been shown to induce apoptosis, providing a
further rationale for therapeutic intervention [26,28].
While the expression and role of thromboxane
synthase has been examined in a number of cancers and
has demonstrated significant promise, this enzyme has
not yet been investigated in NSCLC. Due to the clear
role of COX-2 in NSCLC pathogenesis, investigation of
the downstream TXS enzyme would be of significant
interest and relevance. The aim of this study was there-
fore to examine the expression profile of thromboxane
synthase in NSCLC, relative to matched controls. We
aimed to correlate TXS expression patterns with a range
of clinical parameters, including overall survival (to
determine if it is prognostic in the disease). Finally, we
also wished to examine the effect of both TXS inhibition
and TXS overexpression on in-vitro NSCLC survival
mechanisms.
Methods
Patients and tumour specimens
Patients who had received primary chemotherapy
(neoadjuvant) treatment were excluded from this study.
For protein analysis, a series of 26 fresh-frozen NSCLC
specimens (13 Adenocarcinomas and 13 Squamous Cell
Carcinomas) with corresponding matched normal tissue
from the same individual were collected at surgery at St.
James’s Hospital. All samples were evaluated by a
pathologist immediately following dissection.
F o rg e n e r a t i o no faN S C L Ct i s s u em i c r o a r r a y( T M A ) ,
paraffin blocks from 204 patients who underwent che-
motherapy with surgical resection at St. James’s Hospital
(2000-2005) for NSCLC of varying histology, stage, and
grade were collected. Patients who underwent pre-
operative chemotherapy, or were found to have stage IV
disease were excluded. Patient tumours were staged
according to the tumour-node-metastasis (TNM) classi-
fication and histologically classified according to the
World Health Organization guidelines. The NSCLC tis-
sue samples were classified as 1) adenocarcinoma, 2)
squamous cell carcinoma, and 3) others. Patients range
in age from 41 years to 86 years. Patients were followed
up by the tumour registries for survival time and out-
come with median follow-upo f6 0m o n t h s( r a n g i n g
from 1 to 88 months).
Generation of NSCLC tissue microarrays
Tissue microarrays were assembled using a tissue array-
ing instrument (Beecher Instruments, Silver Spring, MD).
A 3 mm diameter stylet was used for sampling, with
three replicate core samples of tumour taken from differ-
ent regions in each donor block to account for tumour
heterogeneity. Four μM sections of the resulting microar-
ray blocks were cut on a microtome (Leica Microsystems
Inc., IL, USA) and dried onto poly-L-lysine-coated glass
slides (BDH Laboratory Supplies, Poole, England).
RNA isolation and reverse-transcription PCR analysis
A-549 and SKMES-1 cells for RNA analysis were col-
lected in 1 mL of Tri-Reagent (Molecular Research Cen-
ter, OH, USA). Total RNA was subsequently isolated
according to manufacturers’ instructions. RNA quantifi-
cation was determined spectrophotometrically (Nano-
drop technologies, DE, USA), with RNA concentration
subsequently used to carry out cDNA synthesis (reverse-
transcription). First strand cDNA was prepared using
Superscript III according to the manufacturers’ instruc-
tions (Invitrogen Corporation, CA, USA). cDNA was
generated using random primers (Promega, WI, USA),
and synthesis reactions were carried out for 3 h at the
appropriate temperature. Expression of TXS and b-actin
was examined by RT-PCR using previously published
primers [20,29].
PCR cycling conditions were as follows:
b-actin: 95°C for 5 min, followed by 35 cycles of
(1 min at 94°C, 1 min at 56°C, 1 min at 72°C), with a
final extension at 72°C for 10 min.
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94°C, 30 s at 55°C, 45 s at 72°C) with a final extension
at 72°C for 10 min.
b-actin levels were utilized as the internal loading con-
trol for each sample analysed.
Western blot analysis
Primary tissue protein lysates were extracted from
NSCLC specimens and matched normal lung tissue
using Tri-Reagent (MRC), according to the manufac-
turers’ instructions. Protein samples (25 μg) were sepa-
rated by pre-cast SDS-PAGE and transferred to PVDF
membranes. Membranes were probed overnight at 4°C
with a primary antibody directed against thromboxane
synthase (1:250 dilution, Cayman, Michigan, USA). Fol-
lowing probing, blots were stripped and re-probed for
b-actin (1:20,000, Merck Biosciences, Germany) to nor-
malize for loading differences. Densitometric analysis
was carried out on all TXS tumour/normal matched
western blots and corresponding b-actin controls. Ana-
lysis was carried out using TINA (version 4.0) software
(Raytest, Germany). Protein expression was normalized
to b-actin controls, and was expressed as a ratio of TXS
expression: b-actin expression.
Immunohistochemical staining
COX-2 and TXS staining of NSCLC tissue was carried
out manually using Vectastain Elite Kits (Vector labs,
Burlingame, CA, USA). Immunostaining was carried out
using a rabbit polyclonal IgG specific for COX-2 (1:600
dilution, Cayman Chemical), or a rabbit polyclonal IgG
specific for TXS (1:500 dilution, Cayman Chemical).
Slides were incubated in the primary antibody for 1 h at
room temperature (COX-2), or overnight at 4°C (TXS).
Staining was visualised using a ScanScope GL digital
slide scanner and Aperios ImageScope software (Aperio
Technologies Inc., CA, USA).
Quantification of staining intensity
Staining in NSCLC tissue micro-array tissue was blindly
scored and quantified by three independent observers
(M.C.C., K.G. and G.P.). Expression levels within tumour
tissue was quantified across three representative cores
per patient as a product of the staining intensity (0 =
negative, 1 = weak, 2 = moderate, 3 = strong) x percen-
tage cells stained (< 25%, < 50%, < 75%, < 100%). Stain-
ing intensity was quantified under high magnification (x
20), using Aperio Image Scope software (Aperio Tech-
nologies). Expression patterns were correlated with a
range of clinical parameters such as patient demo-
graphics (gender), tumour classifications (tumour sub-
type, stage, grade, and nodal status) and overall survival.
Enzyme immunoassay analysis of metabolite generation
Plasma levels of TXB2 (thromboxane A2 metabolite)
were measured in a retrospective panel of NSCLC
plasma samples and age-matched controls (50 chemo-
naive patient samples, 19 cancer-free controls). Control
samples were taken from patients with no known his-
tory of cancer. Plasma samples were isolated from whole
blood by centrifugation at 3,000 × g for 10 min. Enzyme
i m m u n o a s s a yk i t s( A s s a yD esigns, MI, USA) were used
to determine TXB2 levels in plasma isolated from
NSCLC patients and age-matched controls. The assay
was carried out according to manufacturers’
instructions.
In-vitro experiments
Cell culture and chemicals
Two lung cancer cell lines, A-549 (adenocarcinoma) and
SKMES-1 (squamous cell carcinoma) were obtained
from and the American Type Culture Collection (Rock-
ville, MD, USA). They were maintained in a humidified
atmosphere of 5% CO2 in air at 37°C. A-549 cells were
maintained in F-12 (Hams) medium, supplemented with
10% (v/v) foetal bovine serum (FBS), penicillin strepto-
mycin, and L-glutamine. SKMES-1 cells were main-
tained in Modified Eagle’s Medium + Earle’sm e d i u m
(MEM), supplemented with 10% (v/v) FBS, penicillin
streptomycin, L-glutamine and non-essential amino
acids. Subculturing was carried out when the cells
reached 80% confluency. The selective thromboxane
synthase inhibitor, ozagrel, was obtained from Cayman.
Generation and characterisation of stable transfectant
clones
H u m a nT X A Sc D N Aw a sag i f tf r o mP r o f .K e n n e t hV .
Honn (Wayne State University, Detroit, MA, USA). A
1.5 Kb DNA fragment containing the entire TXAS cod-
ing sequence was digested from pBluescript plasmid
DNA and inserted into the site of the mammalian vec-
tor pcDNA3.1(-) (Invitrogen Corporation, CA, USA) to
generate pcDNA3.1(-)-TXAS. The two mammalian vec-
tor constructs were individually transfected into
SKMES-1 cells. Stable transfection of vector constructs
were carried out using FuGENE 6™ transfection reagent
(Roche Diagnostics Ltd., Sussex, UK). Approximately 3
×1 0
5 cells were cultured in their respective supple-
ment-free medium. Cells were then transfected with
either 1 μg pcDNA-TXS/3.1(-), or pcDNA-3.1(-) (con-
trol vector) in antibiotic-free media, containing 3 μL/mL
FuGENE 6™, according to manufacturers’ instructions.
Following transfection, cells were further incubated for
24 h at 37°C. Antibiotic selection was then carried out
by treating the cells with Geneticin G-418 (800 μg/mL).
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colonies were selected and amplified. RNA and protein
was the isolated from amplified clones isolated in order
to examine relative TXS expression levels. The TXS
clone with the highest TXS expression level was chosen
for further analysis (along with corresponding empty
vector control cells).
Cell proliferation analysis
A-549 and SKMES-1 lung cancer cells were seeded at a
concentration of 5 × 10
3/well into 96-well plates and
allowed to adhere at 37°C overnight. Following over-
night incubation in serum-depleted media, cells were
treated for 24 h with and without various concentrations
( 5 0n M ,5 0 0n M ,5μM) of a selective thromboxane
synthase antagonist (Cayman). Cell proliferation was
then assessed by BrdU cell proliferation assay, according
to the manufacturers’ instructions (Roche).
Annexin-V-FITC/Propidium Iodide Apoptosis Assay
Cells were seeded in 6-well plates (at a dilution of 2.5 ×
10
4,o r5×1 0
4 cells/well), which were allowed to adhere
at 37°C overnight. Following this, cells were incubated
for 48 h or 72 h in serum-depleted media (0.5% FBS).
Cells and supernatants were then collected and trans-
ferred into flow tubes (BD Biosciences, MA, USA) for
annexin-V-FITC apoptosis analysis by flow cytometry
(FACS). Cells were prepared for FACS analysis accord-
ing to manufacturers’ instructions (Roche). Apoptosis
levels were measured using a FACS Caliber flow cyt-
ometer (BD Biosciences), with data analysis carried out
using dot plot analysis.
High content screening analysis
The effects of selective thromboxane synthase inhibition
on apoptosis in A-549 and SKMES-1 cell lines was also
examined by High Content Screening using the GE
Analyser 1000 (GE/Amersham Biosciences, NJ, USA).
Briefly, A-549 and SKMES-1 lung cancer cells were set-
up in 96-well plates, and treated as previously described.
Following treatment, a Multi-Parameter Apoptosis Hit-
Kit was used to assess three fundamental parameters
related to apoptosis (nuclear morphology, mitochondrial
mass/membrane potential and changes in f-actin con-
tent), according to manufacturers’ instructions (Cello-
mics Inc., PA, USA). Stained plates were sealed and run
on a GE Analyser 1000.
Cell death detection ELISA and DNA laddering
A-549 and SKMES-1 lung cancer cells were seeded at a
concentration of 5 × 10
4/well into 12-well plates and
allowed to adhere at 37°C overnight. Following over-
night incubation in serum-depleted media, cells were
treated for 24 h with and without various concentrations
of the selective TXS antagonist, ozagrel (Cayman). The
generation of cytoplasmic histone-associated DNA frag-
ments (mono- and oligo nucleosomes) following apopto-
sis was then measured by Cell Death Detection ELISA
(Roche). Sample preparation and the ELISA procedure
were both carried out according to manufacturers’
instructions. A similar experimental setup was carried
out in 75 cm
2 flasks, and apoptosis confirmed by DNA
laddering analysis using a DNA-laddering kit (Roche).
Cell invasion assay
Tumour cell invasion was examined using a 96-well Cell
Invasion Assay (Chemicon International, CA, USA).
Briefly, 1 × 10
5 cells in 100 μL serum-free media were
added per well to an invasion chamber, which had pre-
viously been rehydrated with serum-free media. The 96-
well plate was then covered and incubated for 24 h at
37°C. Invasion analysis was then carried out according
to manufacturers’ instructions.
Statistical analysis
Statistical comparison of expression levels of these
enzymes between tumour and matched control protein,
and plasma samples was calculated using a 2-tailed Stu-
dents t-test. Correlation analysis was carried out using a
Linear (Pearson) Correlation test. Association between
clinicopathological features and expression of these
enzymes was assessed using a 2-tailed Students t-test for
continuous data. Overall survival was examined using
Kaplan-Meier’s survival curves, with differences in survival
assessed by the log-rank test. Statistical analysis for in-
vitro experiments was carried out using ANOVA, with
post-hoc analysis carried out using Tukey-Kramer multi-
ple comparisons test. Results are expressed as mean ±
SEM, with data taken as significant where p < 0.05. All sta-
tistical analysis was carried out using InStat Statistical
Software Package version 3.0 with survival analysis carried
out using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Thromboxane synthase expression in retrospective NSCLC
protein samples, relative to matched normal controls
Examination of TXS expression in a panel of NSCLC pro-
tein samples revealed an over-expression of TXS in
tumour samples, relative to matched normal controls
(Figure 1A). Densitometric analysis confirmed these obser-
vations, with TXS expression significantly (p < 0.05) higher
in tumour samples, relative to matched normal controls
(0.81 ± 0.1 tumour vs. 0.52 ± 0.06 normal, Figure 1B).
When broken into tumour subtype, increased TXS expres-
sion was observed in 77% of adenocarcinoma (0.74 ± 0.1
tumour vs. 0.54 ± 0.08 normal, not significant, p = 0.08)
and 77% of squamous cell carcinoma (0.88 ± 0.19 tumour
vs. 0.5 ± 0.1 normal, p< 0.05) samples screened (data not
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expression is increased in a significant proportion of
patients with NSCLC.
Thromboxane A2 metabolite levels in NSCLC plasma
samples and age-matched controls
As thromboxane synthase was increased in our retro-
spective panel of tumour/normal matched NSCLC pro-
tein samples, we wished to determine if this increase in
expression at the protein level would be reflected in the
downstream generation of the TXA2 metabolite, TXB2.
TXB2 levels were measured in a panel of NSCLC plasma
samples and age-matched cancer-free controls by enzyme
immunoassay (EIA). Measurement of TXB2 levels in
human plasma would be indicative of circulating levels in
the blood. Thromboxane B2 levels were found to be sig-
nificantly (p< 0.01) higher in plasma samples taken from
patients with NSCLC, relative to age-matched controls
(3307 ± 189 pg/mL versus 2207 ± 317 pg/mL; n = 49
NSCLC patient, 19 cancer-free controls; Figure 1C), sup-
porting previous observations at the protein level.
Examination of the thromboxane synthase expression
pattern in NSCLC tissue samples and matched normal
controls
A panel of retrospective lung tumour (adenocarcinoma
and squamous cell carcinoma) and matched normal tis-
sue sections were stained by IHC for thromboxane
synthase to determine localisation of tissue expression
(n = 10 adenocarcinoma and 10 squamous cell carci-
noma). TXS was found to be weakly expressed in vascu-
lar smooth muscle cells and moderately expressed in
pulmonary epithelial cells of normal tissue (Figure 2A).
In matched tumour sections, TXS was found to be
expressed to a varying degree in both adenocarcinoma
(Figure 2B) and squamous cell carcinoma tissue (Figure
2C). In the tumour supplying vessels, TXS expression
was strong in bronchial epithelial cells (Figure 2D).
Tissue microarray analysis of COX-2 and thromboxane
synthase in NSCLC: correlation with clinical parameters
A 204-patient NSCLC tissue microarray generated using
patients presenting to St. James’s Hospital, Dublin, was
Figure 1 Expression of TXS and its metabolite TXB2 in tumour and matched control patient samples. A) Expression of TXS in a
retrospective panel of tumour/normal matched protein samples. Over-expression of TXS protein was observed in adenocarcinoma and
squamous cell carcinoma samples, relative to matched normal (n = 13/group). B) All blots were stripped and re-probed for b-actin to normalise
for loading differences (N = normal, T = matched tumour). C) Thromboxane metabolite generation in NSCLC plasma samples and age-matched
controls. Plasma levels of the thromboxane metabolite, thromboxane B2, were significantly higher in plasma from NSCLC patients than in age-
matched controls (C; * p< 0.01; n = 49 patient, 19 controls).
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was expressed to a varying degree in NSCLC tumour
tissue. A large number (approximately 30%) of patient
samples were found to be negative for COX-2 expres-
sion. However, COX-2 expression was detected in a
majority of patient samples, where it was found to be
highly localised to specific areas of the tumour tissue.
Quantification of COX-2 expression levels revealed
COX-2 expression was significantly (p< 0.05) higher in
adenocarcinoma tissue, relative to squamous. A signifi-
cantly (p< 0.05) higher expression was also detected in
female patients. COX-2 expression was not found to be
correlated with either tumour stage or nodal status in
our patient cohort, although a significant (p <0 . 0 5 )d i f -
ference in expression was observed between grade 2 and
grade 3 tumours. Correlation of COX-2 expression with
5-year patient survival revealed no significant correlation
with overall survival, although a clear trend was
observed for reduced survival in patients with high
COX-2 expression (p = 0.2). However, COX-2 expres-
sion was significantly (p< 0.01) associated with short-
term (2-year) survival in our patient cohort, suggesting
that this enzyme is prognostic in our study, at least for
shorter-term survival (results shown in Table 1).
NSCLC TMA analysis of thromboxane synthase expres-
sion revealed similar observations to those of COX-2 ana-
lysis. TXS expression levels were significantly (p< 0.001)
higher in adenocarcinoma patients, relative to squamous
cell carcinoma. Expression was also significantly (p< 0.05)
higher in female patients. TXS expression did not corre-
spond with either tumour stage or nodal status. However,
expression levels were significantly (p <0 . 0 5 )l o w e ri n
grade 3 tumours, relative to grade 2. No correlation of
TXS expression with patient survival was observed. It has
been established that TXS activity (and subsequent TXA2
generation) is dependent on COX-2 expression to supply
the PGH2 substrate [22]. It may therefore be of impor-
tance to examine a potential role for COX-2 expression in
combination with TXS expression in patient survival.
Combined analysis revealed COX-2 expression to be sig-
nificantly (p < 0.0001) correlated with that of TXS, with an
r value of 0.34 (data not shown). However, no correlation
of TXS expression in combination with high COX-2 with
patient survival was observed, suggesting that thrombox-
ane synthase is not a prognostic factor in NSCLC (results
shown in Table 1).
Thromboxane synthase expression in NSCLC cell lines:
effects of selective inhibition on tumour cell growth
Two lung cancer cell lines-A-549 (adenocarcinoma) and
SKMES-1 (squamous cell carcinoma)-were screened for
TXS expression by both RT-PCR (Figure 3A) and wes-
tern analysis (Figure 3B). A modest basal expression of
both TXS mRNA and protein was observed in both cell
lines, although mRNA expression in A-549 cells was
higher than that in SKMES-1. The effect of 24 h selec-
tive thromboxane synthase inhibition with ozagrel on
tumour cell proliferation/survival was then examined in
both cell lines by BrdU cell proliferation assay. A signifi-
cant (p< 0.05) reduction in tumour cell proliferation/
survival was observed in A-549 cells following treatment
with 5 μM ozagrel, relative to untreated controls (79 ±
0.5% ozagrel vs. 100% untreated). A non-significant
reduction in tumour cell proliferation/survival was also
observed in these cells following treatment with 50 nM
(85 ± 0.03%) and 500 nM (83 ± 0.04%) ozagrel, relative
to controls (Figure 3C). A significant (p< 0.05) reduction
in tumour cell proliferation/survival was observed in
SKMES-1 cells following 24 h treatment with 500 nM
(86 ± 0.01%) and 5 μM (78 ± 0.02%) ozagrel, relative to
untreated controls (Figure 3D).
Tumour cell apoptosis is increased following selective
thromboxane synthase inhibition
In order to further examine the effect of TXS inhibition
on tumour cell survival pathways, High Content Screen-
ing Analysis of NSCLC cells was carried out following
treatment. Multiparameter analysis of apoptosis signal-
ling was assessed in both NSCLC cell lines following 24
h selective TXS inhibition using the GE In Cell Analy-
ser. The Multiparamater Apoptosis HitKit from Cello-
mics provides High Content Screening qualified
Figure 2 Expression of PGIS and TXS in a retrospective panel
of tumour/normal matched tissue samples. TXS was weakly
expressed in the smooth muscle of normal pulmonary vessels, with
a moderate expression observed in pulmonary epithelial cells (A). In
tumour sections, TXS expression was observed to a varying degree
in both adenocarcinoma (B) and squamous cell carcinoma (C) tissue.
A weak TXS expression was observed in vascular smooth muscle
cells of the tumour vasculature (C), with strong expression observed
in tumour epithelial cells (D). Magnification ×10.
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fundamental parameters of apoptosis. Enlarged nuclei
were stained blue (Hoechst), f-actin, a marker of cytos-
keletal integrity, was stained green (Alexa Flour
® 488
Phalloidin) and mitochondrial mass/potential within the
cells was stained orange/pink (Mito Tracker
® Red). A
notable change in the morphology of both cell lines was
observed following treatment. These changes were char-
acterised by a reduction in nuclear condensation and
mitochondrial mass/potential within the cells, as well as
a reduction in f-actin content (Figure 4A).
Quantification of multi-parameter apoptosis signalling
was carried out using In Cell Analyser software. Selec-
tive TXS inhibition resulted in a reduction in both cellu-
lar f-actin content and mitochondrial mass/potential in
both cell lines (Figure 4B), indicating that the mechan-
ism whereby TXS inhibition reduces tumour cell prolif-
eration/survival in these cells is through induction of
apoptosis.
In order to confirm the observations of the High
Content Screening, a number of alternate apoptosis
assays were carried out on both cell lines following
treatment with ozagrel. These included DNA laddering
and Cell Death Detection ELISA. DNA fragmentation/
laddering was observed in both cell lines following 24
h selective TXS inhibition (500 nM, 5 μMo z a g r e l ;F i g -
ure 4C). In addition Cell Death Detection ELISA
demonstrated increased nucleosome generation in the
cytoplasmic fraction of cell lysates following TXS inhi-
bition with 50 nM (1.5 ± 0.19 fold increase), 500 nM
(1.68 ± 0.3 fold increase) or 5 μM (1.67 ± 0.18 fold
increase) ozagrel in A-549 cells, relative to untreated
controls (Figure 4D). A similar increase in nucleosome
generation was observed in SKMES-1 cells following
treatment with 50 nM (1.24 ± 0.03 fold increase), 500
nM (1.5 ± 0.13 fold increase) or 5 μM (1.65 ± 0.28
fold increase) ozagrel (data not shown). These results
confirm that ozagrel exerts its effects through
Table 1 Correlation of NSCLC TMA staining with clinical parameters
COX-2 Staining Intensity (Mean ±
SEM units)




(n = 124) Male 28.9 ± 3.7 0.03 81.9 ± 3.4 0.04
(n = 73) Female 36.8 ± 4.1 98.6 ± 9.6
Tumour Subtype
(n = 83) Adenocarcinoma 39.5 ± 4.9 0.02 119 ± 7 <
0.0001
(n = 92) Squamous Cell Carcinoma 25.9 ± 3.7 58.9 ± 5.5
Tumour Stage
(n = 105) Stage 1 33.1 ± 3.5 93.3 ± 7.5
(n = 43) Stage 2 35 ± 8.2 0.51 82.7 ± 9.3 0.7
(n = 43) Stage 3 26.9 ± 5 90 ± 9.7
Tumour Grade
(n = 13) Grade 1 27.4 ± 8.2 0.02 104.7 ± 21.7 0.02
(n = 106) Grade 2 38.9 ± 4.4 grade 2
vs.
98 ± 6.4 grade 2
vs.
(n = 64) Grade 3 26.9 ± 5 grade 3 70.4 ± 6.7 grade 3
Nodal Status
(n = 119) Node Negative 35 ± 3.9 0.22 91.7 ± 6.3 0.4
(n = 79) Node Positive 27.6 ± 3.7 83.2 ± 7.1
2-Year Survival (months)
(n = 92) ≤ median value 21.8 ± 0.61 0.008 N/A N/A
(n = 95) ≥ median value 18.8 ± 0.8
Overall Survival (months)
(n = 99) ≥ median value 47.4 ± 3.8 58.5 ± 3.6 months
(n = 98) ≤ median value 54.2 ± 3.2 0.2 52.2 ± 3.7 months 0.32
COX-2/TXS Combined Overall Survival
(months)
(n = 22) High COX-2/Low TXS N/A N/A 45.5 ± 7.9 months 0.38
(n = 51) High COX-2/High TXS 54.1 ± 5 months
Expression profile of COX-2 and TXS in a 204-patient NSCLC TMA: correlation with clinical parameters. Expression levels of COX-2 and TXS in NSCLC TMAs were
correlated with a range of clinical parameters, including patient demographics, tumour classifications and overall survival.
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tion, and nucleosome generation.
Stable over-expression of thromboxane synthase in
SKMES-1 cells
In order to confirm the effects of selective TXS inhibi-
tion, stable clones over-expressing TXS were generated
in SKMES-1 cells. The SKMES-1 cell line was chosen
for stable transfection of TXS as baseline expression of
both RNA and protein levels of this enzyme in this cell
line are relatively low (Figure 3A, B). Following transfec-
tion, TXS over-expression was characterised by both
RT-PCR (Figure 5A) and western analysis (Figure 5B). A
single TXS over-expressing clone was subsequently cho-
sen for further analysis (TXS c l o n e2 ) ,w h i l eac o r r e -
sponding empty vector clone was also selected as a
control.
Thromboxane synthase over-expression increases tumour
cell growth/invasiveness and appears to protect against
apoptosis
The effect of TXS over-expression on tumour cell prolif-
eration/survival was examined by BrdU assay. Wild-type
SKMES-1 cells, TXS over-expressing cells, and their cor-
responding empty vector control were seeded onto 96-
well plates and allowed to adhere overnight. Cells were
then either serum-starved (0.5% FBS media), or incu-
bated in 10% FBS medium for 48 or 72 h. A significant
increase (p < 0.05) in tumour cell growth was observed
in TXS clone 2 when incubated under full-serum condi-
tions for 48 h, relative to empty vector transfected con-
trols (144 ± 2.6% vs. 115 ± 7.1%). A similar effect was
observed when the cells were incubated in serum-
depleted medium for 48 h (182 ± 8.3% clone 2 vs. 123 ±
9.4% empty vector). Empty vector transfected cells
appeared to grow at a faster rate than wild-type cells
under both full-serum (115 ± 7.1% vs.1 0 0±2 . 3 % )a n d
serum-depleted (123 ± 9.4% vs. 100 ± 5.5%) conditions,
although this was not significant in either case (Figure
6A). A similar effect was observed in TXS over-expres-
sing clone 2 following a 72 h incubation, with a highly
significant increase (p < 0.01) in cell proliferation/survi-
val observed under both full-serum (182.7 ± 17% clone
2 vs. 100.2 ± 8.6% empty vector) and serum-starved
(194 ± 12.2% clone 2 vs. 130 ± 11.1% empty vector)
conditions. While no difference in proliferation was
observed between empty vector transfected cells and
wild-type control cells under full-serum conditions
(100.2 ± 8.6% vs. 100 ± 8.1%), proliferation was
increased in empty vector cells following serum-starva-
tion (130 ± 11.1% vs. 100 ± 10.6%), suggesting that
these cells may be more robust under these conditions
(Figure 6B).
TXS expression has been shown to have a potential
role in tumour invasion and metastasis [26]. Invasion
through the extra-cellular matrix (ECM) is an important
Figure 3 Thromboxane synthase expression in NSCLC cells and effects of selective inhibition on tumour cell growth. A modest basal
expression of TXS was observed in A-549 and SKMES-1 cell lines at both the RNA (A) and protein (B) levels. Selective TXS inhibition resulted in a
significant reduction in tumour cell survival in both A-549 (C) and SKMES-1 (D) cell lines. Data is expressed as mean ± SEM, with proliferation
values expressed as a percentage of the controls (* p< 0.05 relative to control, # p< 0.05 relative to control; n = 3).
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expression on tumour-cell invasion was therefore exam-
ined by Cell Invasion Assay. A significant increase in
tumour-cell invasion was observed in TXS-transfected
clone 2, relative to the corresponding empty vector con-
trol cells (165 ± 0.64% vs. 61.4 ± 15.4%). No significant
difference in tumour cell invasion was observed between
empty vector control SKMES-1 cells and wild-type cells
(61.4 ± 15.4% vs. 100 ± 14.7%) (Figure 6C).
In order to further examine the effect of TXS over-
expression on tumour survival pathways in SKMES-1
cells, tumour-cell apoptosis was examined in stable
transfectant clones, corresponding empty vector con-
trols, and wild-type controls by flow cytometry. Stable
TXS over-expression appeared to protect against apop-
tosis in these cells. A reduction in tumour cell apoptosis
was observed in the TXS clone 2 following 48 h (Figure
7A) or 72 h (Figure 7B) serum-starvation, relative to
empty-vector transfected controls (40 ± 5% vs. 67 ± 12%
48 h, 49.6 ± 4.2% vs. 82.2 ± 6.6% 72 h). However,
neither of these effects was found to be statistically sig-
nificant. Additionally, no significant differences in apop-
tosis were observed between wild-type SKMES-1 cells
and empty-vector control cells at either time-point.
Representative dot plots showing percentage apoptosis
in wild-type, empty vector, and TXS over-expressing
clones following 72 h serum-starvation are shown in
Figure 7C-E.
Figure 4 The effects of TXS inhibition on tumour cell apoptosis. A) Apoptosis was induced in a dose-dependant manner following 24 h
treatment with ozagrel, relative to untreated control cells. Cell health following ozagrel treatment was assessed using 3 spectrally distinct
flourophores to examine nuclei, f-actin (marker of cytoskeletal integrity), and mitochondrial mass/potential. Reduced f-actin levels demonstrate a
loss in cellular integrity during apoptosis. Membrane blebbing also occurs and mitochondrial activity occurs, coupled with a loss of potential
across the mitochondrial membrane. These markers were quantified by the Kinetic Scan HCS reader and are represented (B). Similar observations
were made in SKMES-1 cells (data not shown). Apoptosis was confirmed following selective TXS inhibition by Cell Death Detection ELISA and
DNA laddering in both cell lines (A-549 shown as representative). Cell Death ELISA demonstrated increased apoptosis in a concentration
dependant manner, with fold induction expressed as a ratio of control cells (C). DNA laddering was also observed following ozagrel treatment at
both 500 nM and 5 μM concentrations (D).
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The tumour-promoting effects of COX-2 over-expres-
sion may be attributable to specific downstream pro-
ducts of arachidonic acid metabolism [30]. The function
of thromboxane synthase and its prostanoid, thrombox-
ane A2 in the cardiovascular system have been exten-
sively studied and are well known. The enzyme has
been shown to have a major role in maintaining cardio-
vascular haemostasis, mediated through its effects on
platelet activation and aggregation. The impact of
thromboxane synthase on cancer development and pro-
gression has received considerable interest over the past
number of years. Expression of this enzyme has been
shown to promote tumourigenesis via i t se f f e c t so n
tumour growth, angiogenesis and metastasis [20-22,24].
H o w e v e r ,t h er o l eo fT X Si nn o n - s m a l lc e l ll u n gc a n c e r
has not yet been investigated. The aim of the current
study was to examine the expression profile of TXS in
NSCLC and to determine whether expression of this
enzyme is a prognostic factor or potential therapeutic
target in the disease. Our study demonstrates that TXS
Figure 5 Stable over-expression of TXS in SKMES-1 cells.
Following stable transfection, TXS over-expression was characterised
by RT-PCR (A) and western analysis (B).
Figure 6 Effect of stable TXS-over-expression on tumour cell growth and invasion. Following characterisation of transfection efficiency,
both TXS over-expressing and corresponding empty vector control clones were selected and cell proliferation/survival was examined by BrdU
assay following 48 h (A) and 72 h (B) incubations. Data is represented at a percentage of the empty vector control, which was set to 100%. (* p
< 0.05 vs. empty vector, *# p < 0.05 vs. 0.5% FBS empty vector, # p < 0.01 vs. empty vector, $ p < 0.01 vs. 0.5% FBS empty vector). Cell invasion
was examined following 24 h incubation in stable transfected TXS clones (C). Each sample was loaded in triplicate onto the 96-well plate. Data is
taken as a percentage of the empty vector control, which was set to 100%. (* p < 0.05 vs. empty vector, *# p < 0.05 vs. empty vector, ** p <
0.01 vs. empty vector). All data is expressed as mean ± SEM. Statistical analysis was carried out by ANOVA (one-way analysis of variance), with
post-test analysis by Bonferroni multiple comparisons test. n = 3 independent experiments.
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nostic factor in the disease. However our data suggests
that TXS promotes tumour growth and development,
and is therefore a potential therapeutic target in NSCLC.
Examination of TXS expression pattern in matched
tumour/normal protein samples revealed significantly
increased expression in NSCLC samples relative to
matched normal controls. TXS over-expression has been
observed in a variety of other cancer types, including
thyroid [20], bladder [21], prostate [22] and colorectal
cancer [24]. TXS over-expression has been correlated
with significantly reduced patient survival in bladder
cancer [21]. In prostate cancer, its expression was signif-
icantly correlated with advanced stage and grade. In this
study, the authors suggested that TXS activity was
dependant on COX-2 and to a lesser degree, COX-1 to
supply the PGH2 substrate [22,25]. Previous studies in
human lung carcinoma found levels of the downstream
metabolite of TXS, TXB2,t ob es i g n i f i c a n t l yh i g h e ri n
tumour tissues relative to non-tumour controls [31].
Circulating TXS prostanoid levels cannot be measured
quantitatively due to its very short half-life. In order to
determine fractional amounts circulating in the plasma,
the amount of the stable TXA2 metabolite, TXB2 was
measured in a retrospective panel of NSCLC plasma
samples and age-matched controls. TXB2 levels were
significantly higher in patient samples, with basal con-
trol TXB2 levels comparing favourably to previous stu-
dies (unpublished data). Our observation suggests that
circulatory TXB2 levels are increased in NSCLC, which
may potentially impact on a patient’s risk of developing
venous thrombosis. Venous thromboembolism is a fre-
quent cause of cancer-associated mortality [32] and
patients with NSCLC have a 20-fold elevated risk of
thrombosis [33]. In addition, increases in TXB2 expres-
sion have been associated with increased lipid peroxida-
tion and bcl2 expression [31], suggesting that circulating
TXB2 levels may promote tumour formation, partly via
apoptosis evasion. As a result of our findings, we are
setting up a study to prospectively examine the impact
Figure 7 Effect of stable TXS-over-expression on tumour cell survival. Apoptosis was measured in TXS stable transfectants, and
corresponding controls (wild-type and empty vector) following 48 h (A) and 72 h (B) serum-starvation by flow cytometry. Representative dot
plots following 72 h serum starvation are shown for wild-type (C), empty vector (D) and TXS overexpressing (E) cells. Graphical data is
represented at a percentage of the empty vector control, which was set to 100%. Data is expressed as mean ± SEM. n=3 independent
experiments.
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and prognosis in NSCLC.
The role of COX-2 in lung cancer is well established,
with a number of clinical trials examining COX-2 inhi-
bition as a potential therapy for NSCLC [9-11]. COX-2
expression is required for PGH2 and subsequent prosta-
noid generation (including thromboxane A2), and is
therefore of importance for the activity and subsequent
e f f e c t so fT X S .T h i si ss u p p o r t e db yap r e v i o u sr e p o r t
that TXS regulates tumour motility via the COX-2 path-
way in prostate cancer [22]. Thromboxane A2, the pros-
tanoid product of TXS, has also been shown to mediate
COX-2 dependant angiogenesis. Linear correlation ana-
lysis revealed a highly significant association of COX-2
with TXS expression, supporting previous observations
[22]. COX-2 and TXS expression levels were both sig-
nificantly higher in adenocarcinoma patients, relative to
squamous. The significance of these observations is
unclear, but it has been observed that patients with ade-
nocarcinoma are at a higher risk of developing venous
thrombosis than those with squamous cell carcinoma
[33]. A significant increase in COX-2 and TXS expres-
sion was also observed in female patients, relative to
males. While no studies have previously been carried
out to determine a possible gender influence on the
expression of these enzymes in cancer, recent studies in
murine models have shown that levels of constrictor
p r o s t a n o i d ss u c ha sC O X - 2a n dT X A 2 are higher in
females than males [34]. Expression levels of both
enzymes were not altered with either tumour stage or
nodal status. Interestingly, both COX-2 and TXS
expression levels were significantly lower in grade 3
tumours, relative to grade 2. These observations are in
contrast to those in a prostate cancer study [22], but are
supported by previous observations in breast cancer
[35], suggesting that the expression pattern of this
enzyme may vary between cancer types.
COX-2 expression has previously been associated with
reduced patient survival in NSCLC [6-8]. Our study
noted similar observations. While COX-2 expression
was not associated with a significant reduction in long-
term (5-year) survival, statistical significance was
observed for short-term (2-year) patient survival. In con-
trast, no significant correlation of TXS expression with
patient survival was observed, even when TXS expres-
sion was examined in combination with levels of COX-2
expression. While this observation may seem surprising,
given previous findings, similar observations have been
observed in breast cancer patients where low levels of
TXS expression were correlated with tumours of high
grade and a predicted poor clinical outcome [35]. The
authors also found that levels of the thromboxane
receptor (TP) were negatively associated with disease-
free survival, suggesting that the downstream receptor,
as opposed to its corresponding synthase, may be prog-
nostic in the disease [36].
Selective inhibition of TXS has been shown to reduce
tumour cell proliferation/survival in a number of can-
cers including colorectal carcinoma [24], and bladder
cancer [21]. In our study, selective inhibition of TXS
significantly (and dose-dependently) reduced tumour
cell growth in an adenocarcinoma and squamous cell
NSCLC cell line. This was mirrored by a reduction in
thromboxane metabolite (TXB2) generation, as assessed
by enzyme immunoassay of the culture medium (data
not shown). In direct contrast, stable TXS over-expres-
sion significantly increased tumour cell growth in
SKMES-1 cells, implicating this enzyme as a survival
factor and potential therapeutic target in NSCLC. Our
observations are in agreement with previous observa-
tions in a xenograft colorectal cancer model [27], and
suggest that TXS is a potential therapeutic target in
NSCLC pathogenesis. While the effect of TXS inhibition
on healthy cells was not examined, previous studies
have shown that TXS blockade inhibits endothelial cell
migration in response to VEGF or bFGF, suggesting an
effect on normal cellular mechanisms [23]. The signifi-
cantly increased NSCLC TXS levels observed in our
study suggests that TXS inhibition would have a prefer-
ential effect on tumour cells and warrants further inves-
tigation in NSCLC pathogenesis.
Increased apoptosis following TXS inhibition was
demonstrated by High Content Screening (HCS), and
quantified using In Cell Analyser software. Apoptosis
was characterised by a reduction in mitochondrial mass/
potential and f-actin content in both cell lines following
treatment with ozagrel. HCS observations were validated
by DNA laddering and Cell Death Detection ELISA.
These findings are consistent with a recent study by
Moussa et al. in bladder cancer [26]. They are also sup-
ported by our further observations that stable TXS over-
expression appeared to protect against tumour cell
apoptosis, relative to controls. It may therefore be
hypothesised that TXS exerts its effects on tumour cells,
at least in part, via inhibition of apoptosis. In addition
to apoptosis however, TXS and its product, TXA2 have
also been implicated in the regulation of other cancer
survival pathways such as angiogenesis [23], migration
[21,22], invasion [21], and tumour cell metastasis [23].
In our study TXS over-expression significantly increased
the invasive capacity of SKMES-1 cells, suggesting
another survival mechanism associated with over-
expression. In order to further examine the mechanism
underlying the effects of selective TXS inhibition, RT
2
Profiler™ Cancer PathwayFinder PCR arrays were used
to examine the expression of a panel of genes implicated
in tumourigenesis following 24 h treatment with ozagrel
(additional file 1). Notable changes in gene expression
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tosis, angiogenesis and invasion/metastasis. While each
cell line exhibited distinct gene expression profiles fol-
lowing TXS inhibition, a small subset of genes stood out
as being of interest. These included the pro-apoptotic
genes Bax (4-fold increase), Granzyme A (9-fold
increase), and TNF (4-fold increase) in A-549 cells and
anti-apoptotic genes Bcl2 (3-fold decrease) and IGF1 (5-
fold decrease) in SKMES-1 cells (Additional file 2, Fig-
ure S1). The previous observation that increases in cir-
culating TXB2 expression is associated with BCL2
expression lends support to our observations [31]. In
addition to the effects of TXS inhibition on tumour cell
survival mechanisms, examination of downstream
genetic pathways implicated in tumourigenesis is also of
particular interest in NSCLC, with the potential to pro-
vide further insight into the anti-tumour effects of TXS
inhibition.
In conclusion, TXS and its metabolite, TXB2,a r e
over-expressed in NSCLC. While TXS was not found
to be prognostic, our study clearly shows that it is pro-
tumourigenic and may be a target for therapeutic
intervention via induction of apoptosis. Inhibition of
this enzyme may therefore be a suitable therapeutic
approach for NSCLC treatment, either alone, or
in combination with conventional chemotherapeutic
agents.
Additional material
Additional file 1: Examination of changes in cancer-associated gene
expression profile following selective TXS inhibition. Changes in
gene expression profile following selective TXS inhibition were assessed
in both A-549 and SKMES-1 cell lines by quantitative PCR array, using RT
2
Profiler™™ Cancer PathwayFinder arrays.
Additional file 2: Pie charts demonstrating the changes in cancer-
associated gene expression profile following selective TXS
inhibition (in A-549 and SKMES-1 NSCLC cell lines). The results of the
analysis described in additional file 1 are represented graphically in this
additional file (Additional File 2, Figure S1), with pie charts used to group
qRT-PCR changes in gene expression following TXS inhibition into the 6
hallmarks of cancer. Figure S1: Cancer-gene expression profiling following
24 h selective TXS inhibition in A-549 (A) and SKMES-1 (B) cell lines.
Genes were grouped according to the six hallmarks of cancer. These
included genes involved in cell cycle and DNA damage repair, apoptosis/
cell senescence, signal transduction/transcription, adhesion, angiogenesis
and invasion/metastasis.
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